A new article was published in the journal Clinical Pharmacology and Therapeutics

Yan-ou Yang, Victor Sokolov, Alina Volkova, Xing Liu, Cristina Leon, Yuri Kosinsky, Breann Barker, Xuecheng Zhang, Peter Ordentlich, Jennifer Sheng, Xuejun Chen. Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host Disease. Clinical Pharmacology and Therapeutics. 20 December 2024. doi: 10.1002/cpt.3503

In this work, our team has developed a semi-mechanistic PK/PD model for axatilimab, describing intricate interconnections between plasma axatilimab concentration and several biomarkers, including colony-stimulating factor 1, nonclassical monocytic cells, aspartate transaminase and creatine phosphokinase, which was used to substantiate dose and dosing schedule in patients with chronic graft-versus-host disease as a part of the BLA submission to the FDA.